Seroatlas · Human Serome Atlas

LFNG

Beta-1,3-N-acetylglucosaminyltransferase lunatic fringe

Also known as: LFNG_HUMAN, SCDO3

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q8NES3
Gene
LFNG
Ensembl
ENSG00000106003
Chromosome
7
Canonical length
379 aa
Protein class
Disease related genes, Enzymes, Human disease related genes, Potential drug targets, Predicted intracellular proteins
Subcellular location
Nuclear membrane,Golgi apparatus
Secretome location
Intracellular and membrane

OverviewNCBI Gene

This gene is a member of the glycosyltransferase 31 gene family. Members of this gene family, which also includes the MFNG (GeneID: 4242) and RFNG (GeneID: 5986) genes, encode evolutionarily conserved glycosyltransferases that act in the Notch signaling pathway to define boundaries during embryonic development. While their genomic structure is distinct from other glycosyltransferases, these proteins have a fucose-specific beta-1,3-N-acetylglucosaminyltransferase activity that leads to elongation of O-linked fucose residues on Notch, which alters Notch signaling. The protein encoded by this gene is predicted to be a single-pass type II Golgi membrane protein but it may also be secreted and proteolytically processed like the related proteins in mouse and Drosophila (PMID: 9187150). Mutations in this gene have been associated with autosomal recessive spondylocostal dysostosis 3. [provided by RefSeq, May 2018]

Canonical amino-acid sequenceUniProt

379 residues, UniProt reviewed canonical sequence.

>Q8NES3|LFNG
     1  MLKRCGRRLL LALAGALLAC LLVLTADPPP PPLPAERGRR ALRSLAGPAG AAPAPGLGAA
    61  AAAPGALVRD VHSLSEYFSL LTRARRDAGP PPGAAPRPAD GHPRPLAEPL APRDVFIAVK
   121  TTKKFHRARL DLLLETWISR HKEMTFIFTD GEDEALARHT GNVVITNCSA AHSRQALSCK
   181  MAVEYDRFIE SGRKWFCHVD DDNYVNLRAL LRLLASYPHT RDVYVGKPSL DRPIQAMERV
   241  SENKVRPVHF WFATGGAGFC ISRGLALKMS PWASGGHFMN TAERIRLPDD CTIGYIVEAL
   301  LGVPLIRSGL FHSHLENLQQ VPTSELHEQV TLSYGMFENK RNAVHVKGPF SVEADPSRFR
   361  SIHCHLYPDT PWCPRTAIF

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LFNG can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Other membrane
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0.34
Highest tissue expression
72 nTPM

Expression across tissuesHPA

Tissue

  • pancreas: 72 nTPM
  • skin: 55 nTPM
  • stomach: 36 nTPM
  • salivary gland: 32 nTPM
  • basal ganglia: 24 nTPM
  • midbrain: 24 nTPM

Single-cell type

  • monocytes: 79 nCPM
  • bergmann glia: 52 nCPM
  • astrocytes: 46 nCPM
  • cdc: 41 nCPM
  • neuroendocrine cells: 40 nCPM
  • müller glia: 40 nCPM

Immune cell

  • eosinophil: 13 nTPM
  • intermediate monocyte: 7 nTPM
  • non-classical monocyte: 6.6 nTPM
  • basophil: 6.3 nTPM
  • classical monocyte: 5.4 nTPM
  • T-reg: 4.2 nTPM

Brain region

  • thalamus: 64 nTPM
  • midbrain: 60 nTPM
  • medulla oblongata: 57 nTPM
  • hypothalamus: 46 nTPM
  • cerebellum: 46 nTPM
  • basal ganglia: 38 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about LFNG.

Disease | AllUniProt

Conditions LFNG is implicated in, by any mechanism.

  • Spondylocostal dysostosis 3, autosomal recessive (SCDO3) MIM:609813

Disease | GeneticClinVar

10 pathogenic / likely-pathogenic of 331 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.69
gnomAD pLI
0.1
gnomAD missense Z
0.62
DepMap mean gene effect
0.06
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 6% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LFNG as an antibody target. Whether an autoantibody or antibody against LFNG could matter depends on whether native LFNG is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LFNG is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label LFNG as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/LFNG. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...